Intravenous Ciprofloxacin Therapy in Respiratory Infections

Authors

  • Sarah Shahabuddin Department of Medicine State University of New York At Stony Brook
  • Faroque Ahmad Khan State University of New York, Stony Brook, USA

DOI:

https://doi.org/10.5915/24-1-15458

Keywords:

Fluoroquinolones, ciprofloxacin, infection, respiratory tract, sequential therapy

Abstract

DOI: http://dx.doi.org/10.5915/24-1-15458

Of the quinolone class of antimicrobials, only intravenous (IV) ciprofloxacin is currently available for treatment of various bacterial infections. Pathogens causing pneumonia in otherwise healthy adult patients may differ from those found in elderly patients, nursing home residents, alcoholics, and in individuals with debilitating diseases. Nosocomial pneumonias typically involve Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli. Aspiration pneumonia in the community most often involves anaerobes, but in the hospital S. aureus and Gram-negative organisms are commonly found. Based on these clinical and microbiological issues, a comparative evaluation of sequential IV and oral (PO) ciprofloxacin versus other antibiotics were reviewed and the results are summarized in this article. The focus is on the role of sequential intravenous/oral ciprofloxacin in the treatment of lower respiratory tract injection.

Presented at the lMA 24th Annual Convention Long Island, New York, July 1991

Author Biographies

Sarah Shahabuddin, Department of Medicine State University of New York At Stony Brook

M.D.

Department of Medicine
State University of New York At Stony Brook

Faroque Ahmad Khan, State University of New York, Stony Brook, USA

Professor of Medicine, SUNY at Stony Brook.

Master American College of Physicians.

Downloads

Published

1992-01-01

Issue

Vol. 24 No. 1 (1992)

Section

Review Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).